International News

Physicians warming to CBD drug for epilepsy, pharmaceutical maker tells investors

Broad physician adoption of a cannabis-derived epilepsy treatment is boosting sales for the only company with federal permission to sell cannabis products in the United States. London-based GW Pharmaceuticals told investors Monday that it notched $108 million in sales last quarter and $309 million for calendar 2019. The sales figures were released in advance of the company’s […]

Read More

Another German court halts sale of CBD as food without ‘novel’ authorization

Local authorities acted correctly by not allowing sales of CBD products that don’t have a “novel food” authorization, a German court decided, confirming an earlier ruling. The “novel food” classification is given by the European Union to products that have not been significantly consumed before 1997. The Gießen Administrative Court (VG Gießen) said it decided […]

Read More

CBD wellness firm Heavenly Rx to take over Nasdaq-traded drug company

An emerging CBD company plans to take over a Nasdaq-traded pharmaceutical corporation focused on developing cannabinoid pharmaceuticals. Under an agreement announced Tuesday, Heavenly Rx will execute a reverse takeover of Therapix Biosciences. When the proposed deal is complete, the combined entity will be known as Heavenly Rx. Paul Norman, CEO of Heavenly Rx and former […]

Read More

Ruling confirms Germany’s designation that CBD is a ‘novel food’

A court case confirmed that German authorities consider CBD products either a prescription medicine or novel food. The ruling followed the direction of the European Union (EU), which has ruled that the cannabinoid and products containing cannabidiol can’t be yet be sold without additional safety research. The novel foods distinction is given to products if […]

Read More

Losses narrow for GW Pharmaceuticals on dramatic revenue increase

A strong uptick in doctor prescriptions and coverage from health insurers is being credited for solid quarterly revenues for GW Pharmaceuticals. The London-based firm that makes cannabis-derived CBD medicines reported revenue of $91 million for the third quarter ended Sept. 30, up more than 3,500% from the same period a year ago. Despite the revenue […]

Read More

Border seizures of hemp continue despite legalization, lawsuit, importer says

This story has been updated with a section discussing new import/export rules on live hemp plants. A California CBD manufacturer challenging the hemp policies of the U.S. Customs and Border Protection agency says hemp seizures are still taking place despite nationwide legalization and a federal judge’s assurance that border seizures of legal hemp are a thing […]

Read More